Nishikawa, Kazuhiro http://orcid.org/0000-0003-1213-2732
Kawakami, Hisato
Shimokawa, Toshio
Fujitani, Kazumasa
Tamura, Shigeyuki
Endo, Shunji
Kobayashi, Michiya
Kawada, Junji
Kurokawa, Yukinori
Tsuburaya, Akira
Yoshikawa, Takaki
Sakamoto, Junichi
Satoh, Taroh
,
Clinical trials referenced in this document:
Documents that mention this clinical trial
Meta-analysis of three randomized trials of capecitabine plus cisplatin (XP) versus S-1 plus cisplatin (SP) as first-line treatment for advanced gastric cancer
https://doi.org/10.1007/s10147-023-02402-1
Documents that mention this clinical trial
The association of premorbid conditions with 6-month mortality in acutely admitted ICU patients over 80 years
https://doi.org/10.1186/s13613-024-01246-w
Meta-analysis of three randomized trials of capecitabine plus cisplatin (XP) versus S-1 plus cisplatin (SP) as first-line treatment for advanced gastric cancer
https://doi.org/10.1007/s10147-023-02402-1
Robot-assisted mobilisation in the intensive care unit: does it offer relief to mobilising specialists? A qualitative longitudinal study at a German university hospital
https://doi.org/10.1007/s44155-024-00074-4
A novel online calculator based on clinical features and hematological parameters to predict total skin clearance in patients with moderate to severe psoriasis
https://doi.org/10.1186/s12967-023-04847-4
Documents that mention this clinical trial
The association of premorbid conditions with 6-month mortality in acutely admitted ICU patients over 80 years
https://doi.org/10.1186/s13613-024-01246-w
Meta-analysis of three randomized trials of capecitabine plus cisplatin (XP) versus S-1 plus cisplatin (SP) as first-line treatment for advanced gastric cancer
https://doi.org/10.1007/s10147-023-02402-1
A novel online calculator based on clinical features and hematological parameters to predict total skin clearance in patients with moderate to severe psoriasis
https://doi.org/10.1186/s12967-023-04847-4
Robot-assisted mobilisation in the intensive care unit: does it offer relief to mobilising specialists? A qualitative longitudinal study at a German university hospital
https://doi.org/10.1007/s44155-024-00074-4
Article History
Received: 26 June 2023
Accepted: 7 August 2023
First Online: 27 August 2023
Declarations
:
: Kazuhiro Nishikawa has received honoraria for lectures from Bristol-Myers Squibb Co. Ltd., Daiichi-Sankyo Co. Ltd., EA Pharma Co. Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., and Taiho Pharmaceutical Co. Ltd. Hisato Kawakami has received consulting fees from Bristol-Myers Squibb Co. Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd., and Daiichi-Sankyo Co. Ltd.; honoraria from Bristol-Myers Squibb Co. Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd., and Daiichi Sankyo Co. Ltd. Yukinori Kurokawa has received honoraria and research funding from Taiho Pharmaceutical. Taroh Satoh has received departmental research grants from Chugai Pharmaceutical Co. Ltd., Ono Pharmaceutical Co. Ltd., Bristol-Myers Squibb Co. Ltd., Daiichi-Sankyo Co. Ltd., Hutchmed, Parexell, and BeiGene, and honoraria from Eli Lilly Japan K.K., Ono Pharmaceutical Co. Ltd., Bristol-Myers Squibb Co. Ltd., and Daiichi-Sankyo Co. Ltd. All remaining authors declare no conflicts of interest.
: This trial was conducted in compliance with the ethical principles of the Declaration of Helsinki and the Ethical Guidelines for Clinical Studies of the Japanese Ministry of Health, Labour and Welfare. This trial was approved by the institutional review boards or ethics committees at all participating centers.